Entretinib is a multi-target tyrosine kinase inhibitor used to treat NTRK fusion positive solid tumors and ROS1 positive non-small cell lung cancer. Although the therapeutic effect is significant, its adverse reactions also need to be actively managed. The following focuses on coping strategies for taste disorders, dizziness, and weight gain.

1、 Coping with taste disorders

1.1 Common manifestations

The incidence of dyspepsia is about 40% to 50%, often manifested as metallic, salty, or taste loss, affecting appetite and quality of life.

1.2 Intervention measures

Adjust food taste: Use sour seasoning (lemon juice, vinegar) or vanilla, spices to enhance flavor and mask metallic taste.

Pre meal oral care: Rinse your mouth with soda water or diluted salt water before meals to remove any residual odors in your mouth.

Avoid metal utensils: Use ceramic or plastic utensils instead to reduce the metallic smell and irritation.

Supplementing with zinc supplements: Short term supplementation with zinc supplements under the guidance of a physician can help restore taste.

Psychological support: Inform patients that taste disorders are usually reversible and mostly recover 4-6 weeks after discontinuation of medication.

2、 Management strategies for dizziness

2.1 Mechanism of occurrence

Enqutinib related dizziness (with an incidence rate of about 38%) is often related to the effects of the drug on the vestibular system or central nervous system, and is often mild to moderate.

2.2 Handling Measures

Slow posture transition: Slow down movement from lying down to sitting, sitting to standing to prevent worsening dizziness caused by orthostatic hypotension.

Ensure adequate drinking water: Drink 1.5-2L of water daily to maintain effective blood volume.

Avoid dangerous activities: Avoid driving, working at heights, or operating precision instruments during the early stages of medication.

Medication in divided doses: If dizziness is related to medication time, you can consult a physician to adjust the medication time or take it in divided doses (depending on the dosage form).

Medication assistance: For severe dizziness, short-term use of anti dizziness drugs (such as betamethasone) may be considered, and other causes such as otolith should be ruled out.

3、 Control and monitoring of weight gain

3.1 Characteristics of occurrence

Enqutinib causes weight gain (with an incidence rate of about 25%), mostly occurring 3-6 months before treatment, mainly related to the drug's effects on appetite regulation and metabolism.

3.2 Intervention Measures

Dietary management: Prioritize the intake of high-quality protein (fish, chicken breast, soy products) and reduce refined sugar and saturated fat.

Regular exercise: ≥ 150 minutes of moderate intensity aerobic exercise (such as brisk walking and swimming) per week, combined with resistance training, to help control body fat.

Regular monitoring: Weigh once a week, record the trend of changes, and detect rapid weight gain early.

Examination of edema: if the weight increases by more than 2kg in a short period (within one week), it is necessary to be alert to fluid retention and timely assess the cardiac and renal functions.

Multidisciplinary collaboration: Individuals with significant weight gain can be referred to a clinical nutrition department to develop personalized dietary plans.